36 results about "Biopterin" patented technology

The invention describes a nutraceutical composition and method for preventing / treating cancer or augmenting chemotherapy in advanced stage malignancies; comprised of [1] tumoricidal herbs; beth root, galbanum, gromwell root, wild yam, balm of gilead bud, frankincense, [2] an antiproliferative herb; speranskia [3] a natural lactic acid dehydrogenase (LDH) inhibitor, 2′,3,4′5,7-pentahydroxyflavone or cinnamon, [4] alkalizing agents: calcium, magnesium, potassium or bicarbonate salts, barley grass, chlorella and spirulina [5] at least one quinone and [6] at least one agent capable of maximizing oxidative mitochondrial function preferably riboflavin, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin and a pharmaceutically acceptable carrier.

To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants.A method for porducing a biopterin derivative represented by the formula (6):wherein R1 and R2, which are the same or different from each other, each represents a hydrogen atom, an alkyl group, or an aryl group, comprising:reacting a compound belonging to triacetoxy-5-deoxy-L-arabinose phenylhydrazones represented by the formula (4):wherein R1 and R2 are the same as defined above,with 6-hydroxy-2,4,5-triaminopyrimidine (5) under catalytic influence of a Lewis acid in an aqueous solvent.

Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.

An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen for or diagnose subjects at high risk for developing a psychiatric, neuropsychiatric, or neurological disorders. The assay of the GCH1 genotype, with or without biopterin or a BH4 or BH4 system assay, may also be used to determine antipsychotic or mood stabilizer medication, as well as other treatments. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.

The invention discloses an accurate, quick and high-throughput method for detecting neopterin and biopterin in the urine of a human body. The method comprises the following steps: analyzing a urine sample which is pre-treated by liquid chromatography on a chromatographic column which is a reverse bonded silica gel column; performing gradient elution with a mobile phase which is methanol and ammonium acetate buffer solution; and detecting with a fluorescent detector. The method is low in cost and simple in pre-treatment, can realize batch-processing detection to optimize the chromatographic process, shorten the analyzing time and greatly improve the throughput of sample, and is especially suitable for requirement of clinical and daily detection for the chromatographic process.

The invention relates to a preparation method of L-erythro biopterin used as a preparation intermediate body of a clinically used medicament (R)-2-amido-6-[(1R, 2S)-1,2-dihydroxy propyl]-5,6,7,8-tetrahydro-4(3H)-pteridine ketone hydrochloride for treating atypical hyperphenylalaninemia, which belongs to the technical field of medicinal chemistry. The preparation method sequentially comprises the steps of: reacting L-(+)-arabinose 1 with alkyl hydrosulfide by acetalization; adding sulfonyl chloride for generating a sulfonation reaction; reducing and removing sulfonyl ester; removing reduced sulfur aldehyde protective groups; reacting with hydrazine for obtaining a hydrazine compound; reacting with estolide or the sulfonyl chloride; reacting with 2,4,5-3-amino-pyrimidine ketone; adding an oxidant; and removing acyl for obtaining the L-erythro biopterin. The invention ensures deodorizing equipment is not installed on a reaction system by utilizing Odourless mercaptan, thereby saving costand optimizing a working environment; and the invention has mild reaction condition of each step, short period and easy operation.

The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and / or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.